Somryst

Pear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics

by

Dig­i­tal health firm Pear goes pub­lic, rais­ing $175 mil­lion (phar­mafo­rum):

Pear will make its debut on the exchange today after com­bin­ing with Thim­ble Point – a spe­cial pur­pose acqui­si­tion com­pa­ny (SPAC) – in a deal that side­stepped the con­ven­tion­al ini­tial pub­lic offer­ing (IPO) route and has pro­pelled its val­u­a­tion to around $1.6 bil­lion … Pear spe­cialis­es in pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) based on cog­ni­tive behav­iour­al ther­a­py (CBT) tech­niques that can deliv­ered remote­ly to [patients via a dig­i­tal device. It has three apps approved by the FDA, includ­ing reSET and reSET‑O for peo­ple liv­ing with sub­stance and opi­oid use dis­or­ders, respec­tive­ly, and a tool for chron­ic insom­ni­acs called Som­ryst. [Read more…] about Pear Ther­a­peu­tics rais­es $175M and goes pub­lic via SPAC deal rais­ing the pro­file of pre­scrip­tion dig­i­tal therapeutics

Trend: Harnessing digital tech to improve mental health and wellness

by

From mind­ful­ness apps to vir­tu­al ther­a­py ses­sions, dig­i­tal tools offer instant access to well­ness resources (The Globe and Mail):

In 2015, Brie Code was work­ing at lead­ing video game com­pa­ny Ubisoft as lead arti­fi­cial intel­li­gence pro­gram­mer when she real­ized that many peo­ple she knew – about half, by her esti­ma­tion – found video games bor­ing. [Read more…] about Trend: Har­ness­ing dig­i­tal tech to improve men­tal health and wellness

The FDA clears Somryst, Pear’s digital therapeutic to treat chronic insomnia

by

Pear gets FDA clear­ance for insom­nia ther­a­peu­tic (Med­C­i­ty News):

“Pear Ther­a­peu­tics received mar­ket­ing autho­riza­tion for its third prod­uct — a dig­i­tal ther­a­peu­tic intend­ed to treat chron­ic insom­nia. Called Som­ryst, the app is avail­able by pre­scrip­tion only. It con­sists of a nine-week pro­gram that includes cog­ni­tive behav­ioral ther­a­py and restrict­ing sleep to a lim­it­ed win­dow of time [Read more…] about The FDA clears Som­ryst, Pear’s dig­i­tal ther­a­peu­tic to treat chron­ic insomnia

Trend: Pharma industry warming up to digital therapeutics

by

– Som­ryst app by Pear Therapeutics

Dig­i­tal ther­a­peu­tics have poten­tial but com­mer­cial suc­cess unproven (Van­tage):

“Devel­op­ing drugs to treat dis­or­ders of the cen­tral ner­vous sys­tem is famous­ly fraught with dif­fi­cul­ty. Sev­er­al com­pa­nies, includ­ing Pear Ther­a­peu­tics and Dthera, are tak­ing a wild­ly dif­fer­ent approach: dig­i­tal ther­a­peu­tics. These are pieces of soft­ware designed to treat dis­ease that are reg­u­lat­ed, pre­scribed and even paid for as if they were drugs … Pear is so far the only com­pa­ny to have brought a dig­i­tal ther­a­peu­tic to mar­ket – but it is by no means the only com­pa­ny in this space. Akili Inter­ac­tive has­filed for FDA approval of AKL-T01, a com­put­er game designed to treat ADHD, and [Read more…] about Trend: Phar­ma indus­try warm­ing up to dig­i­tal therapeutics

Can digital Cognitive Behavioral Therapy (CBTi) become the universal first-line treatment for insomnia?

by

__________

Pear Ther­a­peu­tics’ dig­i­tal insom­nia ther­a­peu­tic will put FDA’s Pre­Cert frame­work through its paces (Mobi­Health­News):

“Pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Pear Ther­a­peu­tics announced late last week that it has filed an FDA mar­ket­ing autho­riza­tion for Som­ryst, its dig­i­tal cog­ni­tive behav­ioral ther­a­py for the treat­ment of adults with chron­ic insom­nia and depression.

While an approval from the agency would mark the third autho­rized pre­scrip­tion dig­i­tal ther­a­peu­tic for Pear [Read more…] about Can dig­i­tal Cog­ni­tive Behav­ioral Ther­a­py (CBTi) become the uni­ver­sal first-line treat­ment for insomnia?